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Abstract
Purpose The effectiveness of cardiac rehabilitation (CR)
in patients with coronary artery disease (CAD) is moder-
ated by negative emotions and clinical factors, but no
studies evaluated the role of positive emotions. This study
examined whether anhedonia (i.e. the lack of positive
affect) moderated the effectiveness of CR on health status
and somatic and cognitive symptoms.
Methods CAD patients (n = 368) ﬁlled out the Hospital
Anxiety and Depression Scale (HADS) to assess anhedonia
at the start of CR, and the Short-Form Health Survey
(SF-36) and the Health Complaints Scale (HCS) at the start
of CR and at 3 months to assess health status and somatic
and cognitive symptoms, respectively.
Results Adjusting for clinical and demographic factors,
health status improved signiﬁcantly during the follow-up
(F(1,357) = 10.84, P = .001). Anhedonic patients repor-
ted poorer health status compared with non-anhedonic
patients, with anhedonia exerting a stable effect over time
(F(1,358) = 34.80, P\.001). Somatic and cognitive
symptoms decreased over time (F(1,358) = 3.85, P = .05).
Anhedonics experienced more beneﬁts in terms of somatic
and cognitive symptoms over time (F(1,358) = 13.00,
P\.001).
Conclusion Anhedonic patients reported poorer health
status and higher levels of somatic and cognitive symptoms
prior to and after CR. Somatic and cognitive symptoms
differed as a function of anhedonia over time, but health
status did not. Anhedonia might provide a new avenue for
secondary prevention in CAD.
Keywords Anhedonia  Cardiac rehabilitation 
Health complaints  Health status  Positive affect
Introduction
Cardiac rehabilitation (CR) has shown to be effective in
improving clinical outcome [1] and health status [2], and in
reducing mortality [3] in patients with established coronary
artery disease (CAD). However, the effectiveness of CR
seems to be moderated by both clinical and psychological
factors [4, 5]. Regarding psychological factors, most
attention has been paid to the detrimental effects of nega-
tive affect, such as depression [6], anxiety [7], and general
distress [8], thereby neglecting the role of positive affect.
Positive affect can be described in terms of joy, cheerful-
ness, and happiness [9]. Importantly, positive and negative
affect are not merely opposite ends of a continuum [10],
with the possibility that both types of affect can be present
simultaneously.
In the general cardiovascular literature, there is an
increased interest in the role of positive affect on clinical
outcomes. In a recent study, emotional vitality, a concept
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against incident CAD [11]. In patients with established
CAD, a positive relation was found between happiness and
a decrease in the number of hospital readmissions after
90 days [12]. To date, studies on the relationship between
positive affect–related constructs and survival have shown
inconsistent results [13–17]. Anhedonia (i.e. the lack of
positive affect) has been shown to independently predict
the combined endpoint of adverse clinical events and
mortality 1 year after an acute coronary syndrome [17] and
in patients following implantation of coronary-artery stents
[18], even after controlling for clinical depression and
severity of depressive symptoms [17].
Apart from clinical outcomes, studies on patient-cen-
tered outcomes have been advocated, as these may help
bridge the gap between research and clinical outcome [19].
To date, no studies have focused on anhedonia and patient-
centered outcomes in cardiac patients. Hence, the objective
of the current study was to prospectively examine the
associations between anhedonia and patient-centered out-
comes, deﬁned as health status and somatic and cognitive
symptoms, in CAD patients attending CR.
Method
Study design and participants
Consecutive patients with CAD (n = 368; response
rate = 71.2%) referred to CAPRI (cardiac rehabilitation
program at the Rotterdam Organization for Cardiac Reha-
bilitation, Rotterdam, The Netherlands) between March
2004 and October 2005, participating in the identiﬁcation
of subgroups of HEART patients that may not beneﬁt
optimally from CArdiac Rehabilitation (HEARTCARE)
study, comprised the sample for the current study. Patients
diagnosed with chronic heart failure by their treating car-
diologist (due to participation in another study within the
institution) and those with insufﬁcient knowledge of the
Dutch language to be able to complete questionnaires were
excluded from participation. A ﬂow-chart of the patient
selection is provided in Fig. 1. Patients were asked to
complete a set of psychological questionnaires at baseline
and at 3-month follow-up (i.e. prior to and after completion
of the rehabilitation program). The present study was set up
as a between-subjects design, and not as a randomized
controlled trial, given that CR has been shown to decrease
mortality. Hence, it would be unethical to withhold CR
from patients [6].
The study protocol was approved by the medical ethics
committee of the Erasmus Medical Center, Rotterdam. The
study was conducted according to the Helsinki Declaration
and every patient provided written informed consent.
Contents of the rehabilitation program
The program was multi-factorial comprising an introduc-
tion module, a physical exercise component, modules on
risk factors, stress management, diet, medication, weight
loss, and smoking cessation, with the possibility of having
individual counseling by a psychiatrist, psychologist, or
social worker if necessary.
Materials
Demographic and clinical variables
Demographic variables included gender, age, educational
level, marital status, and employment status. Clinical
variables, obtained from the patients’ medical records,
included initial diagnosis, cardiac history prior to the
referral event (i.e. previous myocardial infarction (MI),
coronary artery bypass graft surgery (CABG), or percuta-
neous coronary intervention (PCI)), prescribed medica-
tions, smoking, and risk factors (i.e. hypercholesterolemia,
hypertension, diabetes, family history, renal insufﬁciency,
chronic obstructive pulmonary disease (COPD), and liver
insufﬁciency).
Anhedonia
Anhedonia (i.e. the lack of positive affect) was assessed
with the Hospital Anxiety and Depression Scale (HADS) at
baseline [20, 21]. Items are scored on a 4-point Likert scale
ranging from 0 to 3. Previous research using factor analysis
n=519
n=408
n=368
n=379
n=111
n=29
n=11
Patients eligible for participation 
Baseline assessment, but no follow-up
Follow-up assessment, but no baseline
Too many missing data on questionnaires
Total number of participants
Fig. 1 Flow chart of patient selection
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123of the HADS has identiﬁed a psychometrically sound
positive subscale in patients with CAD [18]. In line with
this study, the Positive Affect scale was computed by
summing up four items (i.e. items 2, 4, 12, and 6) (range
[0–12], mean = 9.79 ± 2.54) [18]. Anhedonia was deﬁned
as a score B 7 on the Positive Affect scale (i.e. one SD
below the mean). The mean scores on the Negative Affect
(range [0–12], mean = 3.08 ± 2.56) and the Relaxed
Affect scale (range [0–9], mean = 6.03 ± 2.30) were in
line with this study as well [18].
In order to cross-validate the three subscales derived
from the HADS, patients also ﬁlled out the Global Mood
Scale (GMS) to assess Positive and Negative Affect
[22–24]. The 20 items are answered on a 5-point Likert
scale ranging from 0 (‘not at all’) to 4 (‘extremely’). Both
subscales have good internal consistency (a = .94 and
a = .93, respectively) [24], and test–retest reliability over a
3-month period for both subscales is adequate (Negative
Affect = 0.66 and Positive Affect = 0.57) [22].
Health status
The Dutch version of the Short-Form Health Survey
(SF-36) was administered both at baseline and at 3 months
to assess generic health status [25, 26]. All 36 items are
answered according to standardized response choices and
contribute to eight subscales: Physical Functioning, Social
Functioning, Role Limitations due to Physical Functioning,
Role Limitations due to Emotional Functioning, Mental
Health, Vitality, Bodily Pain, and General Health. Raw
scores were transformed to summary scores according to
standard scoring procedures. Subscale scores range from
0 to 100, with higher scores indicating better levels of
functioning. In addition, by using scoring algorithms, these
eight scales can be summarized in two component scores:
the Mental Component Score (MCS) and the Physical
Component Score (PCS) [27]. The validity and reliability
of the SF-36 are good [26].
Somatic and cognitive symptoms
The 24-item Health Complaints Scale (HCS), a disease-
speciﬁc measure, was administered to assess somatic and
cognitive symptoms at baseline and at 3-month follow-up
[28]. Both the somatic and the cognitive complaints scale
consist of 12 items that are scored on a 4-point Likert scale
ranging from 0 (‘not at all’) to 4 (‘extremely’), with a score
range from 0 to 48. A high score on both subscales indi-
cates more symptoms. Internal consistency is good
(.89\a\.91) and test–retest reliability has proven to be
adequate (r = .69) in patients with established CAD [28,
29]. This instrument has been shown to be responsive to tap
treatment-related changes following CR [30].
Statistical analyses
Principal Component Analysis (PCA) with varimax rotation
was used toexplore the factorial structure of the HADS.The
scree plot was used as a criterion for the number of factors
to be extracted. KMO and Bartlett’s test of sphericity were
used as ﬁt-indices. KMO (.92) and Bartlett’s test of sphe-
ricity (v
2(91) = 1966, P\.001) indicated that the data
were appropriate for carrying out a PCA. The construct
validity of the HADS scales (i.e. Positive Affect, Negative
Affect, and Relaxed Affect) was determined by computing
Pearsons’ product-moment correlations between the GMS
Positive and Negative Affect scales. Discrete variables were
compared with the Chi-square test and continuous variables
with Student’s t-test for independent samples. Analyses
were adjusted for multiple comparisons by means of Bon-
ferroni corrections (a/number of comparisons). To examine
differences in health status between anhedonic and non-
anhedonic patients prior to and after CR, we used multi-
variable analysis of variance (MANOVA) in order to adjust
for multiple comparisons, given that the SF-36 comprises
two summary scores (PCS and MCS) and the HCS com-
prises two subscales (somatic and cognitive symptoms).
Multivariable analysis of covariance (MANCOVA) was
performed to adjust for the effect of potential confounders
on the relationship between anhedonia and health status and
somatic and cognitive symptoms. A priori [31], we decided
to include age, gender, comorbidity (COPD, diabetes, or
renal insufﬁciency), the use of nitrates, antidepressant and
anxiolytic medications, and receiving individual counseling
as covariates in the analyses based on the literature [7, 32,
33]. In addition, we added the derived HADS Negative
Affect scale in order to control statistically for a measure of
negative affect, also to investigate whether negative and
positive affect are merely the opposites of two ends of a
continuum [10], or whether they can be present at the same
time. This approach is in line with previous studies on the
effects of anhedonia in cardiac patients [17, 18]. Post hoc
paired samples t-tests were conducted to determine differ-
ences in summary scores for the SF-36 and scale scores of
the HCS for anhedonic and non-anhedonic patients
separately.
A post hoc power analysis showed that with an assumed
effect-size of .20, a = .05, and a power of 95%, a sample
size of 327 patients was required to detect statistically
signiﬁcant differences in SF-36 component scores and HCS
scores pre- and post-CR (repeated measures design, within-
between interaction). This assumption was met, since
analyses were performed on 368 patients. All statistical
tests were two-tailed, and P\.05 was used to indicate
statistical signiﬁcance. Statistical analyses were performed
using SPSS 17.0 for Windows (SPSS Inc., Chicago,
Illinois, USA).
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Patient characteristics
Completers (n = 368) and non-completers (n = 151) of
the CR program did not differ on baseline demographic and
clinical characteristics.
The prevalence of anhedonia was 20.1% in the current
sample. Patient baseline characteristics stratiﬁed by anhe-
donia are presented in Table 1. Differences emerged
between anhedonic and non-anhedonic patients on baseline
demographic and clinical characteristics, with anhedonic
patients more frequently smoking (P = .002) and taking
more often anti-depressant and anxiolytic medications
(P\.001 and P = .007, respectively) compared with non-
anhedonic patients. In addition, trends were found for non-
anhedonic patients being more likely to have a partner and
less likely to have individual counseling as part of CR.
Characteristics of the HADS Positive Affect scale
PCA conﬁrmed the previously identiﬁed three-factor
structure [18], comprising Positive Affect (4 items), Neg-
ative Affect (4 items), and Relaxed Affect (3 items)
(Table 2). The items 8 (‘‘I feel as if I am slowed down’’),
9 (‘‘I get a sort of frightened feeling like ‘butterﬂies’ in the
stomach’’), and 10 (‘‘I have lost interest in my appear-
ance’’) were excluded from further analyses, because these
items loaded diffusely on the three factors (high cross-
loadings), had relatively low item-correlations, and did not
contribute to the internal consistency of any of the scales.
The derived HADS Positive Affect subscale showed a
signiﬁcant correlation with the GMS Positive Affect sub-
scale (r = .53, P\.001) and a signiﬁcant negative cor-
relation with the GMS Negative Affect subscale (r =
-.47, P\.001), conﬁrming the construct validity of this
derived HADS subscale. In addition, the derived HADS
Negative Affect subscale was signiﬁcantly positively cor-
related with the GMS Negative Affect scale (r = .50,
P\.001) and negatively correlated with the GMS Positive
Affect subscale (r =- .38, P\.001). The HADS Relaxed
Affect subscale showed signiﬁcant correlations with both
of the GMS Positive Affect and Negative Affect scales
(r = .36 and r =- 38, both Ps\.001, respectively).
Anhedonia as a determinant of health status
MANOVA with repeated measures demonstrated a sig-
niﬁcant within-subjects effect for time (F(1,366) = 222.63,
P\.001), indicating that health status improved following
CR. The time by Anhedonia interaction effect was not
signiﬁcant, indicating that Anhedonia had a stable effect
on health status over time (F(1,366) = 1.33, P = .25).
However, anhedonic patients reported signiﬁcantly poorer
health status than non-anhedonic patients (F(1,366) =
64.53, P\.001). Mean scores on health status pre- and
post-CR stratiﬁed by anhedonia are presented in Fig. 2.
MANCOVA showed a main effect for time (F(1,357)
= 10.84, P = .001), indicating that the overall improve-
ment in health status after CR as seen in unadjusted
analysis remained when correcting for potential con-
founders. Furthermore, a trend was found for the interac-
tion effect for time by anxiolytic medications, denoting that
patients using anxiolytic medications reported impaired
health status pre- and post-CR compared with patients not
using anxiolytic medications (F(1,357) = 3.45, P = .06).
Comorbidity, age, gender, smoking, nitrate use, use of
antidepressants, individual counseling, and the HADS
Negative Affect scale did not interact with CR (all
Ps[.05). The time by anhedonia interaction effect was
not signiﬁcant, indicating that anhedonia had a stable effect
on health status over time (F(1,357) = .23, P = .63). The
between-subjects effect for anhedonia remained signiﬁcant,
showing that anhedonic and non-anhedonic patients dif-
fered on self-reported health status (F(1,357) = 34.80,
P\.001). The main effects for age (F(1.357) = 3.85, P =
.05), comorbidity (F(1,357) = 4.82, P = .03), the HADS
Negative Affectivity scale (F(1,357) = 98.24, P\.001),
and individual counseling (F(1,357) = 3.90, P = .05)
were signiﬁcant.
Paired samples t-tests showed that anhedonic patients
reported improvements on both the MCS and the PCS
(t(73) =- 5.51 and t(73) =- 5.21, both Ps\.001).
Likewise, non-anhedonic patients reported improvements
on the MCS and the PCS (t(293) =- 7.52 and t(293) =
-12.48, both Ps\.001).
Anhedonia as a determinant of somatic and cognitive
symptoms
MANOVA with repeated measures yielded a signiﬁcant
main within-subjects effect for time, indicating a decrease
in somatic and cognitive symptoms following CR
(F(1,366) = 96.11, P\.001). The interaction effect for
time by anhedonia was signiﬁcant, showing that anhedonia
did not exert a stable effect over time on somatic and
cognitive symptoms (F(1,366) = 11.79, P\.001). Finally,
the between-subjects main effect for anhedonia was sig-
niﬁcant, denoting that anhedonic and non-anhedonic
patients reported different levels of somatic and cognitive
symptoms (F(1,366) = 94.59, P\.001). Mean scores on
somatic and cognitive symptoms pre- and post-CR, strati-
ﬁed by anhedonia, are presented in Fig. 3.
In repeated measures MANCOVA, the main effect for
time was signiﬁcant, indicating that after controlling for
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123covariates, somatic and cognitive symptoms decreased
during the 3-month follow-up period (F(1,357) = 3.75,
P = .05). The interaction effect for time by anhedonia
remained signiﬁcant after controlling for covariates
(F(1,357) = 3.86, P = .05). Likewise, the main between-
subjects effect for anhedonia remained signiﬁcant
(F(1,357) = 13.00, P\.001). The main between-subjects
effects for the HADS Negative Affect scale (F(1,357) =
123.46, P\.001) were signiﬁcant.
Post hoc analyses showed that anhedonic patients
reported a decrease in somatic as well as cognitive symp-
toms following CR (t(73) = 5.48 and t(293) = 5.22, both
Ps\.001). Likewise, non-anhedonic patients also reported
a decrease in somatic and cognitive symptoms after
attending the CR program (t(293) = 7.07 and t(293) =
6.54), both Ps\.001).
Discussion
Studies on the role of psychological factors in CR pro-
grams have merely focused on the role of negative affect.
In contrast, little is known about the effects of positive
affect in CAD. To the best of our knowledge, this is the
Table 1 Demographic and clinical data stratiﬁed by anhedonia
a
Total sample (n = 368) Anhedonia (n = 74) No anhedonia (n = 294) P
Socio-demographics
Males 290 (78.8) 58 (78.4) 232 (78.9) .92
Age, mean (SD) 58.0 (10.2) 57.7 (10.1) 58.1 (10.3) .77
Having a partner 330 (89.7) 62 (83.8) 268 (91.2) .06
Clinical variables
Cardiac event prior to index event
b 299 (81.3) 60 (81.1) 239 (81.3) .97
Diabetes Mellitus 54 (14.7) 13 (17.6) 41 (13.9) .43
Dyslipidemia 185 (50.3) 42 (56.8) 143 (48.6) .21
Hypertension 122 (33.2) 27 (36.5) 95 (32.3) .50
COPD
c 28 (7.6) 6 (8.1) 22 (7.5) .86
Currently smoking 32 (8.7) 13 (17.6) 19 (6.5) .002
d
Medication
ACE-inhibitors 215 (58.4) 47 (63.5) 168 (57.1) .32
Calcium-antagonists 42 (11.4) 5 (6.8) 37 (12.6) .16
Nitrates 118 (32.1) 15 (20.3) 103 (35.0) .02*
Statins 298 (81.0) 62 (83.8) 236 (80.3) .49
Aspirin 277 (75.3) 57 (77.0) 220 (74.8) .70
Diuretics 66 (17.9) 10 (13.5) 56 (19.0) .27
Anti-depressants 15 (4.1) 10 (13.5) 5 (1.7) \.001
d
Anxiolytics 31 (8.4) 12 (16.2) 19 (6.5) .007
d
Cardiac rehabilitation components
e
Introduction 144 (44.4) 29 (45.3) 115 (44.2) .88
Risk factors 251 (77.0) 46 (70.8) 205 (78.5) .18
Nutrition/Dietary advice 238 (73.0) 43 (66.2) 195 (74.7) .16
Medication 196 (59.0) 38 (57.6) 158 (59.4) .79
Physical exercise 327 (98.5) 64 (97.0) 263 (98.9) .26
Stress management 61 (18.4) 8 (1214) 53 (20.0) .14
Smoking cessation 26 (7.8) 4 (6.1) 22 (8.3) .55
Weight loss 53 (16.0) 11 (16.7) 42 (15.8) .86
Individual counseling 48 (14.5) 14 (21.2) 34 (12.8) .08
a Results are presented as n(%) unless otherwise stated
b CABG, MI, or PCI
c COPD = Chronic obstructive pulmonary disease
d P\.05
e Due to missing data for 36–44 patients, analyses were conducted on available data
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123Table 2 Factor structure of the HADS
a
HADS Items Factor I
b
Positive affect
Factor II
b
Negative affect
Factor III
b
Relaxed affect
6 I feel cheerful .73 -.20 .27
2 I still enjoy the things I used to enjoy .69 .24
4 I can laugh and see the funny side of things .72 -.24 .30
12 I look forward with enjoyment to things .73
3 I get a sort of frightened feeling as if something awful is about to happen .81
13 I get sudden feelings of panic .75
5 Worrying thoughts go through my mind -.37 .69 -.25
1 I feel tense or wound up -.42 .54 -.30
7 I can sit at ease and feel relaxed -.33 -.38 .64
14 I can enjoy a good book or TV program .31 .66
11 I feel restless as if I have to be on the move .81
Internal consistency (Cronbach’s a) .83 .81 .67
HADS = Hospital Anxiety Depression Scale
a Loadings\.20 are not displayed
b Items assigned to a factor are presented in bold-face
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Fig. 2 Mean health status scores pre- and post-CR stratiﬁed by
anhedonia. MANOVA with repeated measures. A high score repre-
sents better health status. Note: SDs range from 6.94 to 11.24. Main
effect for Time F(1,357) = 10.84, P = .001; Main effect for
Anhedonia F(1,357) = 34.80, P\.001; Interaction for Time*Anhe-
donia F(1,357) = .23, P = .63. CR Cardiac rehabilitation
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Fig. 3 Mean somatic and cognitive symptoms pre- and post-CR
stratiﬁed by anhedonia. MANOVA with repeated measures. Note:
SDs range from 7.40 to 12.73. Main effect for Time F(1,357) = 3.75,
P = .05; Main effect for Anhedonia F(1,357) = 13.00, P\.001;
Interaction for Time*Anhedonia F(1,357) = 3.86, P = .05. CR
Cardiac rehabilitation
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123ﬁrst study to demonstrate that anhedonic patients, i.e. the
lack of positive affect, reported more impaired health status
and higher levels of health complaints prior to and after
CR attendance compared with non-anhedonic patients.
Furthermore, the current study pointed out that patients’
health status improved and somatic and cognitive symp-
toms decreased in both anhedonic as well as non-anhedonic
patients over time. In addition, we found an interaction
effect for anhedonia by time for somatic and cognitive
symptoms, indicating that anhedonic patients reported
more beneﬁt from CR in terms of reduction in somatic and
cognitive symptoms. The interaction effect for time by
health status was not signiﬁcant.
Our study was in line with previous ﬁndings, showing
that CR may improve health status [2] and diminish
somatic and cognitive symptoms [28]. However, in the
present study, we were also able to identify a speciﬁc
subgroup of patients—namely anhedonic patients—who
consistently reported impaired health status and higher
levels of somatic and cognitive symptoms despite CR
attendance. The importance of anhedonia has been dem-
onstrated previously in CAD, with anhedonia being a risk
factor for major clinical adverse events following implan-
tation of coronary-artery stents [18], and the combined
endpoint of adverse clinical events and all-cause mortality
[17]. The present study elaborates on these ﬁndings by
showing that in a large sample of CR patients, patient-
centered outcomes vary as a function of the level of
anhedonia as well.
In addition, in this study, we replicated ﬁndings on the
underlying factorial structure of the HADS. Originally, this
instrument was developed to assess depressive and anxious
symptomatology in hospitalized patients [20, 21]. How-
ever, two recent studies suggest that it is also possible to
derive a measure of anhedonia from the HADS [18, 34].
Hence, with the HADS, it is possible to tap into several
psychological constructs that have been shown to impact
on patient well-being and prognosis in CAD without
increasing patient burden, making it an opportune instru-
ment to use in clinical practice. In line with these two other
studies, we found that HADS assesses Negative Affect,
Relaxed Affect, and Positive Affect. The construct validity
of these subscales was conﬁrmed by the signiﬁcant medium
to large correlations with the GMS, an instrument that
previously has been shown to valid and reliably assess
positive and negative affect [22–24]. Furthermore, the
three derived HADS scales were shown to be internally
consistent (.83\a\.67).
The notion of positive and negative affect not just
merely being the opposite two ends of a continuum [10],
and the possibility that both types of affect can be present
simultaneously, broadens the scope. The present study
supports this notion, as the effects of anhedonia remained
signiﬁcant after controlling for the confounding effects of
negative affect. The combined effects of negative and
positive affect, i.e. the interaction between those two types
of affect, might reﬁne ﬁndings and contribute to a fuller
understanding of the role of affect in the context of CAD.
Limitations of the current study must be acknowledged.
First, we were not able to control for markers of disease
severity, (e.g. left ventricular ejection fraction) as these
were not consistently collected in the current study.
Moreover, in the present study, we only evaluated the
effect of anhedonia on short-term patient-centered out-
comes. Whether these improvements remain over time is
unknown, but it has been shown that the effects of CR on
health status remain over time [35, 36]. Further, patients
diagnosed with chronic heart failure were excluded in the
current study, due to participation in another study. Results
from the current study can therefore not be generalized to
this speciﬁc patient group. Fourth, information on psychi-
atric diagnoses and objective outcomes, such as exercise
capacity, are lacking. Finally, the present study was based
on a between-subjects design and improvements in health
outcomes cannot be attributed to CR, due to the lack of a
control-group. Strengths of the study comprise the large
sample size and the use of valid and reliable instruments to
assess patient-centered outcomes. In addition, both generic
as well as disease-speciﬁc questionnaires were adminis-
tered to evaluate CR in CAD patients.
From a clinical point of view, studies on anhedonia pave
the way for the development of new interventions for
secondary prevention. Positive affect has been shown to be
associated with biological indices of cardiac disease in
healthy individuals, like salivary cortisol, systolic blood
pressure, and inﬂammatory markers [37–39]. However, up
to now, most studies have focused on the detrimental
effects of negative affective states, like distress [8] and
depressive symptoms [6] on CR outcome. Our results
indicate that anhedonia is also of importance in the context
of CR. Consequently, incorporating and encouraging the
development of skills to experience more positive affect
might contribute to increased beneﬁts from CR programs.
Cognitive-behavioral therapy and mindfulness-based stress
reduction have been shown to improve positive affect in
medically ill patients [40, 41], and in older depressed
patients at increased cardiovascular risk [42], and might be
effective in enhancing positive affect in patients attending
CR.
Future studies are warranted to further determine the
role of anhedonia on hard outcomes like (re-)hospitaliza-
tion, major clinical adverse events (MACE), and survival.
Anhedonia, or the lack of positive affect, independently
predicted major clinical adverse events following implan-
tation of coronary-artery stents [18], and the combined
endpoint of MACE and all-cause mortality in post-MI
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study is of importance as health status has been shown to
predict mortality in CAD patients [43], and patient-cen-
tered outcomes and the identiﬁcation of its determinants
have been advocated to bridge the gap between research
and clinical practice [19].
In conclusion, the present study showed that anhedonic
CAD patients reported poorer health status and higher
levels of somatic and cognitive symptoms prior to and after
CR in comparison with non-anhedonic patients. Further-
more, health status improved and somatic and cognitive
symptoms decreased in both anhedonic and non-anhedonic
patients. Somatic and cognitive symptoms pre- and post-
CR changed differentially for anhedonic and non-anhe-
donic patients, with anhedonic patients reporting more
changes in somatic and cognitive symptoms. These ﬁnd-
ings underscore the importance of studying positive affect
within the context of CR.
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